BBLG - Bone Biologics inks supply deal with MTF Biologics for demineralized bone matrix

Bone Biologics (OTCPK:BBLG) signed a supply agreement with nonprofit organization MTF Biologics for demineralized bone matrix (DBM). The company said MTF Biologics provides one of the orthopedic industry’s largest portfolios of allograft tissue. Bone Biologics noted that it is developing a bone graft substitute product consisting of rhNELL-1 and a carrier, to be supplied by MTF Biologics, for the initiation and improvement of bone formation. The supply agreement provides material for the company's planned 30-patient pilot study, and later for its planned U.S. pivotal study in spine fusion patients. "As we prepare to commence human clinical studies, we are delighted to partner with MTF Biologics, a highly-regarded industry innovator whose bone matrix will now comprise half of our combination product," said Bone Biologics CEO Jeff Frelick.

For further details see:

Bone Biologics inks supply deal with MTF Biologics for demineralized bone matrix